|

Retifanlimab Clinical Trials

14 actively recruiting trials across 11 locations

▲ +1 trial since May 2026

Also known as: 2226345-85-1, INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012 +5 more

Pipeline

Phase 1: 3Phase 2: 5Phase 3: 1Phase 1/2: 5

Top Sponsors

  • University of Washington1
  • University of California, San Diego1
  • Stephen Bagley, MD, MSCE1
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1
  • Scott R. Plotkin, MD, PhD1

Indications

Other2 trials

A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)
Phase 2
Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)
Phase 2

Phoenix, Arizona2 trials

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Mayo Clinic Hospital

Phase 1
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Mayo Clinic-Comprehensive Cancer Center-Breast Clinic

Phase 3

Scottsdale, Arizona1 trial

Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

Mayo Clinic in Arizona

Phase 2

La Jolla, California1 trial

Retifanlimab and Ruxolitinib In Solid Malignancies

University of California, San Diego Moores Cancer Center

Phase 1/2

Los Angeles, California1 trial

Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)

UCLA Medical Center

Phase 2

Baltimore, Maryland1 trial

Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma

Johns Hopkins Medical Institution

Phase 1

Bethesda, Maryland1 trial

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

National Institutes of Health Clinical Center

Phase 1/2

New York, New York1 trial

Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

Memorial Sloan Kettering Cancer Center

Phase 1/2

Portland, Oregon1 trial

Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

OHSU Knight Cancer Institute

Phase 1/2

Philadelphia, Pennsylvania1 trial

All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma

University of Pennsylvania

Phase 2

Houston, Texas1 trial

A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)

The University of Texas M. D. Anderson Cancer Center

Phase 1

Seattle, Washington1 trial

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

Fred Hutch/University of Washington Cancer Consortium

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.